James Mallinson

Oxford Spin-out Equity Management (OSEM) is wholly-owned subsidiary of University of Oxford. The firm headquartered at UK. Since 2008, OSEM is responsible for spinout companies.

Glycoform Ltd. develops pharmaceutical products. The firm's novel synthetic glycoprotein, GLY510, is designed for the treatment of anemia. It provides services in the areas of therapeutic proteins, drug targeting using glycosylation, and enzyme activated pro-drug technology. The company was founded by Benjamin G. Davis and Antony J. Fairbanks in November 2002 and is headquartered in Abingdon, UK

Crysalin Ltd. develops crysalin lattice technology for protein structure determination. Its portfolio includes crysalins, a protein-based nanotechnology for application in protein structure determination, as well as biosensor development and optoelectronics. The company was founded by Martin Noble and John Sinclair in June 2007 and is headquartered in Oxfordshire, the United Kingdom.

Oxford Photovoltaics Ltd. develops and commercialize perovskite-based technology. Its technology can be coated on architectural glass to allow large buildings to generate a significant proportion of their electricity demand, effectively turning them into vertical solar farms. The firm investors include MTI partners, Longwall Venture Partners LLP, Parkwalk, University of Oxford (OSEM). The company was founded by Kevin Arthur and Henry Snaith in December 2010 and is headquartered in Kidlington, the United Kingdom.

Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom.

Orthox Ltd. develops tissue regenerative implants. The firm?s products include FibroFix Meniscus and FibroFix Cartilage. The company was founded by Nicholas James Vavasour Skaer and Oliver Kessler in 2008 and is headquartered in Abingdon, the United Kingdom.

Oxford Biotrans Ltd. develops and commercializes enzymatic process technologies that produce chemical compounds. The firm produces chemicals using ‘green’ biotransformation technology to starting materials into initial focus is on flavors and fragrances using its proprietary understanding of P450 enzyme catalyst technology. The company was founded by Luet Lok Wong in 2013 and is headquartered in Milton Park, the United Kingdom.

Oxstem Ltd. develops cell programming therapies. The company is headquartered in Oxford, the United Kingdom.

Oxford Electromagnetic Solutions Ltd. designs and develops cloud-based, end-to-end smart asset management system. The firm offers OXEMS tag, Application, detector and database products. The company was founded in 2010 and is headquartered in Oxford, the United Kingdom.